July 4, 2009


H. Ballentine Carter, M.D.

Professor of Urology, Oncology
Johns Hopkins Medicine

Director, Division of Adult Urology
Brady Urological Institute


    Free Access to abstracts at PubMed

  
Journal Articles
JOURNAL ARTICLES
  1. Gold JP, Canizaro P, Kazam E, Carter HB, Kuchta N, and Shires GT. The reliability of the results of ultrasound detection of fluid collection in the early postceliotomy period. Surgery, Gynecology and Obstetrics, 161: 5-8, 1985.

  2. Carter HB, Riehle RA, Jr., Koizumi JH, Amberson J, and Vaughan ED, Jr. Fine needle aspiration of the abnormal prostate: A cytohistologic correlation. J Urol, 135: 294-298, 1986.

  3. Carter HB, Naslund EB, and Riehle RA, Jr. Variables influencing radiation exposure during extracorporeal shock wave lithotripsy: A review of 298 treatments. Urology, 30(6): 546-550, 1987.

  4. Riehle RA, Jr, Carter HB, and Vaughan ED, Jr. Quantitative and crystallographic analysis of voided stone fragments after ESWL. J Endourology, 1(1): 37-44, 1987.

  5. Carter HB, Amberson J, Bander NH, Badalament R, Gorelick J, Vaughan ED, Jr., and Whitmore WF, Jr. Newer diagnostic techniques for bladder cancer. Urologic Clinics of North America, 14(4): 763-769, 1987.

  6. Carter HB and Coffey DS. Cell surface charge in predicting metastatic potential of aspirated cells from the Dunning rat prostatic adenocarcinoma model. J Urol, 140: 173, 1988.

  7. Carter HB and Isaacs JT. Experimental and theoretical basis for hormonal treatment of prostatic cancer. Seminars in Urology, Vol. 6 (4):262-268, 1988.

  8. Carter HB, Hamper UM, Sheth S, Sanders RC, Epstein JI, and Walsh PC. Evaluation of transrectal ultrasound in the diagnosis of prostate cancer. J Urol, 142: 1008-1010, 1989.

  9. Carter HB, Partin AW, and Coffey DS. Prediction of metastatic potential in an animal model of prostate cancer: Flow cytometric quantification of cell surface charge. J Urol, 142:1338-1341, 1989.

  10. Carter HB and Isaacs JT. Why do cells metastasize? World J Urol, 8: 2-5, 1990.

  11. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh P.C. Prostate-Specific Antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol, 143: 747-752, 1990.

  12. Carter HB, Piantadosi S, and Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol, 143: 742-746, 1990.

  13. Carter HB, Partin AW, Epstein JI, and Walsh PC. Relationship between PSA and residual tumor volume in stage A prostate cancer. J Urol, 144: 1167-1171, 1990.

  14. Carter HB and Coffey DS. The prostate: An Increasing medical problem. Prostate, 16: 39-48, 1990.

  15. Carter BS, Carter HB, and Isaacs JT. Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate, 16: 187-197, 1990.

  16. Epstein JI, Christensen WN, Steinberg GD, Carter HB, and Walsh PC. Comparison of DNA ploidy and nuclear size, shape, and chromatin irregularity in tissue sections and smears of prostatic carcinoma. Analytical and Quantitative Cytology and Histology, 12(5): 352-358, 1990.

  17. Carter HB, Brem RF, Tempany CM, Yang A, Epstein JI, Zerhouni EA, and Walsh PC. Nonpalpable prostate cancer: Detection with MR Imaging. Radiology, 178: 523-525, 1991.

  18. Larsen MP, Carter HB, and Epstein JI. Can stage A1 tumor extent be predicted by transurethral resection tumor volume, percent or grade? Study of 64 stage A1 radical prostatectomies with comparison to prostates removed for stages A2 and B disease. J Urol, 146: 1059-1063, 1991.

  19. Epstein JI, Pizov G, Steinberg GD, Carter HB, Pitcock R, Armas OA, Partin A, and Walsh PC. Correlation of prostate cancer nuclear deoxyribonucleic acid, size, shape and Gleason grade with pathologic stage at radical prostatectomy. J Urol, 148: 87-91, 1992.

  20. Carter HB, Pearson JD, Metter JE, Brant L J, Chan DW, Andres R, Fozard JL, and Walsh PC. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA, 267: 2215-2220, 1992.

  21. Carter HB, Morrell CH, Pearson JD, Plato, CC, Metter EJ, Chan DW, Fozard JL, and Walsh PC. Estimation of prostatic growth using serial prostate specific antigen measurements in men with and without prostate disease. Cancer Res, 52: 3323-3328, 1992.

  22. Steiner MS, Burnett AL, Brooks JD, Brendler CB, Stutzman RE, and Carter HB. Tubularized neourethra following radical retropubic prostatectomy. J Urol, 150:407-410, 1993.

  23. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, and Walsh PC. The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. J Urol, 150:110-114, 1993.

  24. Ronnett BM, CarMichael MJ, Carter HB, and Epstein JI. Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels? J Urol, 150:386-389, 1993.

  25. Carter HB and Pearson JD. PSA velocity: A new concept for the diagnosis of early prostate cancer. Urologic Clinics of North America, 20(4): 665-670, 1993.

  26. Carter HB. Early Detection Of Prostate Cancer: Another View. Primary Care and Cancer, 13: 34-36, 1993.

  27. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, and Walsh PC. Evaluation of serum prostatic specific antigen velocity after radical prostatectomy to distinguish local recurrence versus distant metastases. Urology, 43: 649-659, 1994.

  28. Partin AW, Criley SR, Steiner MS, Hsieh K, Simons JW, Lumadue J, Carter HB, and Marshall FF. Serum ferritin as a clinical marker for renal cell carcinoma: Influence of tumor volume. Urology, 45:211-217, 1995.

  29. Cadeddu JA, Pearson JD, Partin AW, Epstein JI, and Carter HB. Relationship between changes in prostate-specific antigen and prognosis of prostate cancer. Urology, 42: 383-389, 1993.

  30. Carter HB and Pearson JD. Evaluation of changes in PSA in the management of men with prostate cancer. Seminars In Oncology 21:554-559, 1994.

  31. Pearson JD and Carter HB. Natural history of changes in prostate-specific antigen in early-stage prostate cancer. J Urol, 152:1743-1748, 1994.

  32. Pearson JD, Morrell CH, Landis PK, Carter HB, and Brant LJ. Mixed-effects regression models for studying the natural history of prostate disease. Stat Med, 13:587-601, 1994.

  33. Carter HB, Pearson JD, Metter EJ, Chan DW, Andres R, Fozard JL, Rosner W, and Walsh PC. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate, 27:25-31, 1995.

  34. Carter HB, Pearson JD, Waclawiw Z, Metter EJ, Chan DW, Guess HA, and Walsh PC. Prostate-specific antigen variability in men without prostate cancer: The effect of sampling interval and number of repeat measurements on prostate-specific antigen velocity. Urology, 45:591-596, 1995.

  35. Caddedu JA, Pearson JD, Lee BJ, Landis P, Partin AW, Epstein JI, and Carter HB. Relationship between changes in prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia. Urology, 45:795-800, 1995.

  36. Morrell CH, Pearson JD, Carter HB, Brant LJ. Estimating unknown transition times using a piecewise nonlinear mixed-effects model in men with prostate cancer. J Amer Stat Ass, 90:45-53, 1995.

  37. Schoenberg MP, Carter HB, and Epstein JI. Ureteral frozen section analysis during cystectomy: Reassessment. J Urol, 155:1218-1220, 1996.

  38. Partin AW, Piantadosi S, Subong ENP, Kelly CA, Hortopan S, Chan DW, Wolfert RL, Rittenhouse HG, and Carter HB. Clearance rate of serum-free and total PSA following radical retropubic prostatectomy. Prostate, 7:35-39, 1996.

  39. Pannek J, Subong ENP, Jones KA, Marschke PLS, Epstein JI, Chan DW, Carter HB, Luderer AA, and Partin AW. The role of free/total PSA in the prediction of final pathological stage for men with clinically localized prostate cancer. Urology, 48(6A):51-54, 1996.

  40. Pearson JD, Luderer AA, Metter EJ, Partin AW, Chan DW, Fozard JL, and Carter HB. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. Urology, 48(6A): 4-9, 1996.

  41. Thiel RP, Oesterling JE, Wojno KJ, Partin AW, Chan DW, Carter HB, Stamey TA, Prestigiacomo AR, Brawer MK, Petteway JC, Carlson G, and Luderer AA. Multicenter comparison of the diagnostic performance of free prostate-specific antigen. Urology, 48(6A):45-50, 1996.

  42. Partin AW and Carter HB. The use of prostate specific antigen and free/total prostate specific antigen in the diagnosis of localized prostate cancer. Urologic Clinics of North America, 23:531-540, 1996.

  43. Thiel R, Pearson JD, Epstein JI, Walsh PC, and Carter HB. The role of prostate specific antigen velocity in prediction of final pathological stage in men with localized prostate cancer. Urology, 49:716-720, 1997.

  44. Carter HB, Partin AW, Luderer A, Metter EJ, Landis T, Chan DW, Fozard JL , and Pearson JD. Percentage of free prostate specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology, 49:379-384, 1997.

  45. Carter HB, Sauvageot J, Walsh PC, and Epstein JI. Prospective evaluation of men with stage T1c adenocarcinoma of the prostate. J Urol, 157:2206-2209, 1997.

  46. Epstein JI, Walsh PC, Sauvageot J, and Carter HB. Utility of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol, 158:1886-1890, 1997.

  47. Carter HB, Epstein JI, Chan DW, Fozard JL, and Pearson JD. Recommended prostate-specific antigen testing intervals for detection of curable prostate cancer. JAMA, 277:1456-1460, 1997.

  48. Carter HB and Pearson JD. PSA Velocity And Repeated Measures Of PSA. Urologic Clinics of North America 24:333-338, 1997.

  49. Silver RI, Partin AW, Epstein JI, Chan DW, Carter HB, Jeffs RD, and Gearhart JP. Prostate-specific antigen in men born with bladder exstrophy. Urology, 49:253-256, 1997.

  50. Carter HB and Epstein JI. Prediction of significant cancer in men with stage T1c adenocarcinoma of the prostate. W J Urol, 15:359-363, 1997.

  51. Carter HB. Nonpalpable prostate cancer detected in the prostate-specific antigen era. W J Urol, 15:239-330, 1997.

  52. Guess HA, Pearson JD, Carter HB, Brant LJ, and Fozard JI. Receiver operating curves for subjects with a previously normal test- Example: prostate specific antigen testing. Journal of Epidemiology and Biostatistics, 2:161-169, 1997.

  53. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, Wolfert R, Carter HB. Nonpalpable (stage T1c) prostate cancer: Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160: 2407-2411, 1998.

  54. Argani P, Carter HB, and Epstein JI. Isolated vasculitis of the seminal vesicle. Urology, 52:131-133, 1998.

  55. Carter HB, Lanids PK, Metter E J, Fleisher LA, Pearson JD. Prostate Specific Antigen (PSA) Testing Of Older Men. JNCI 91(20):1733-1737, 1999.

  56. Carter HB, Epstein JI, and Partin AW. The influence of age and prostate specific antigen on the chance of curable prostate cancer among men with non-palpable disease. Urology, 53:126-130, 1999.

  57. Epstein JI, Walsh PC, Akingba G, Carter HB. The significance of prior benign needle biopsies in men subsequently diagnosed with prostate cancer. J Urol, 162:1649-52, 1999.

  58. Williams AM, Simon I, Landis PK, Moser C, Christens-Barry W, Carter HB, Metter EJ, and Partin AW. Prostatic growth rate determined from MRI data: Age-related longitudinal changes. J Androl, 20:474-480, 1999.

  59. Simons JW, Mikhak B, Chang J-F, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete GM-CSF using ex-vivo gene transfer. Cancer Res 59:5160-8, 1999.

  60. Carter HB, Pearson JD. Prostate Specific Antigen (PSA) Testing For Early Diagnosis of Prostate Cancer: Formulation of Guidelines. Urology 54: 780-786, 1999.

  61. Epstein JI, Lecksell K, Carter HB. Prostate cancer sampled on sextant needle biopsy: Significance of cancer on multiple cores from different areas of the prostate. Urology 54:291-294,1999.

  62. Carter HB. A PSA threshold of 4.0ng/mL for early detection of prostate cancer: The only rational approach for men age 50 years and above. Urology 55(6):796-799, 2000.

  63. Harman SM, Metter EJ, Blackman MR, Landis PK, and Carter HB. Insulin like growth factors and binding proteins do not improve prediction of prostate cancer when prostate specific antigen level is known. J Clin Endocrinol Metab 85: 4258-4265, 2000.

  64. Ross K, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate specific antigen screening strategies for prostate cancer detection. JAMA 284: 1399-1405, 2000.

  65. Goldschlag B, Afzal N, Carter HB, Fleisher LA. Is predonation of autologous blood rational for radical retropubic prostatectomy? J Urol 164:1968-72, 2000.

  66. Feneley MR, Landis P, Simon I, Metter EJ, Morrell CH, Carter HB, Walsh PC. Today men with prostate cancer have larger prostates. Urology 56:839-842, 2000.

  67. Potter SR, Carter HB. The role of prostate-specific antigen velocity in prostate cancer early detection. Curr Urol Rep 1:15-9, 2000.

  68. Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol 2000; 46 Suppl:S67-72.

  69. Epstein JI, Walsh PC, Carter HB. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 166:1688-1691, 2001.

  70. Epstein JI, Walsh PC, Carter HB. The importance of posterolateral needle biopsies in the detection of prostate cancer. Urology 57:1112-1116, 2001.

  71. Carter HB. Rationale for earlier and less frequent PSA testing. Urology 58:639-641, 2001.

  72. Wu CL, Carter HB, Naqibuddin M, Fleisher LA. Effect of local anesthetics on patient recovery after transrectal biopsy. Urology 57:925-929, 2001.

  73. Parsons JK, Schoenberg MS, Carter HB. Incidental renal tumors: Casting doubt on the efficacy of early intervention. Urology 57:1013-1015, 2001.

  74. Carter HB, Landis PK, Epstein JI, Walsh PC. Expectant management of prostate cancer with curative intent. Eur Urol 39 Suppl 4:24, 2001.

  75. Brooks JD, Metter EJ, Chan DW, Sokoll LJ, Landis P, Nelson WG, Muller D, Andres R, Carter HB. Plasma Selenium Level Before Diagnosis and the Risk of Prostate Cancer Development. J Urol 166:2034-2038, 2001.

  76. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate specific antigen (PSA) predict the long term risk of prostate cancer: Results from the Baltimore Longitudinal Study of Aging. Urology 58:411-6, 2001.

  77. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of stage T1c prostate cancer with curative intent: Preliminary results. J Urol 167:1231-1234, 2002.

  78. Wright EJ, Fang J, Metter EJ, Partin AW, Landis PK, Chan DW, Carter HB. Prostate Specific Antigen Predicts The Long-Term Risk Of Prostate Enlargement: Results From The Baltimore Longitudinal Study of Aging. J Urol 167:2484-2488, 2002.

  79. Fang J, Metter EJ, Landis P, Carter HB. PSA Velocity for assessing prostate cancer risk in men with PSA levels between 2.0-4.0ng/mL. Urology 59: 889-894, 2002.

  80. Berndt SI, Carter HB, Landis PK, Tucker KL, Hsieh LJ, Metter EJ, Platz EA. Calcium intake and prostate cancer risk in a long-term aging study: The Baltimore Longitudinal Study of Aging. Urology 60:1118-1123, 2002.

  81. Brant LJ, Sheng SL, Morrell CH, Verbeke GN, Lesaffre E, Carter HB. Screening for prostate cancer using random-effects models. J R Statist Soc A 166:51-62, 2003.

  82. Carter HB. Informed consent for prostate-specific antigen screening. Urology 61:13-14, 2003.

  83. Hsieh LJ, Carter HB, Landis PK, Tucker KL, Metter EJ, Newschaffer CJ, Platz EA. Association of energy intake with prostate cancer in a long-term aging study: Baltimore Longitudinal Study of Aging (United States). Urology 61:297-301, 2003.

  84. Khan MA, Partin AW, Carter HB. Expectant Management of Localized Prostate Cancer. Urology 62:793-799, 2003.

  85. Bhasin S, Singh AB, Phong Mac R, Carter HB, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: Recommendations for standardized monitoring plan. J Andrology 24:299-311, 2003.

  86. Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PW, Partin AW, Veltri RW. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 170: 2274-8, 2003.

  87. Hubbard JS, Rohrmann S, Landis PK, Metter EJ, Muller DC, Andres R, Carter HB, Platz EA. Association of Prostate Cancer Risk with Insulin, Glucose, and Anthropometry in the Baltimore Longitudinal Study of Aging. Urology 63:253-258, 2004.

  88. Carter HB, Metter EJ, Wright J, Landis P, Platz EA, Walsh PC. Prostate specific antigen and all cause mortality: Results from the Baltimore Longitudinal Study of Aging. JNCI 96:557-558, 2004.

  89. Carter HB. Prostate Cancers in Men with Low PSA Levels — Must We Find Them? N Engl J Med 350:2292-2294, 2004.

  90. Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC. Anatomic extent of lymph node dissection: Impact on men with clinically localized prostate cancer. J Urol 172:1840-4, 2004.

  91. Carter HB, Isaacs WB. Improved Biomarkers For Prostate Cancer: A Definite Need. JNCI 96:813-814, 2004.

  92. Allaf ME, Carter HB. Update on watchful waiting for prostate cancer. Curr Opin Urol 2004;14:171-5.

  93. Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, Landis PK, Metter EJ, and Carter HB. Nonsteroidal Anti-inflammatory Drugs and Risk of Prostate Cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005; 14:390-396.

  94. Hernandez DJ, Epstein JI, Trock BJ, Tsuzuki T, Carter HB, Walsh PC. Radical retropubic prostatectomy. How often do experienced surgeons have positive surgical margins when there is extraprostatic extension in the region of the neurovascular bundle? J Urol 2005; 173:446-9.

  95. Ross KS, Guess HA, Carter HB. Estimation of Treatment Benefits When PSA Screening for Prostate Cancer is Discontinued at Different Ages. Urology 66:1038-42, 2005.

  96. Carter HB, Landis P, Wright EJ, Parsons JK, Metter EJ. Can a Baseline PSA Level Identify Men Who Will Develop Lower Urinary Tract Symptoms Later in Life? J Urol 173:2040-3, 2005.

  97. Haffner MC, Landis PD, Saigal CS, Carter HB, Freedland SJ. Health related quality of life outcomes after anatomic retropubic radical prostatectomy in the PDE 5 era: Impact of neurovascular bundle preservation. Urology 2005; 66:371-6.

  98. Berndt SI, Carter HB, Landis PK, Hallfrisch J, Rohrmann S, Metter EJ, Platz EA. Prediagnostic plasma vitamin C levels and the subsequent risk of prostate cancer. Nutrition 21:686-90, 2005.

  99. Freedland SJ, Haffner MC, Landis PK, Saigal CS, Carter HB. Obesity Does Not Adversely Affect Health-Related Quality-of-Life Outcomes After Anatomic Retropubic Radical Prostatectomy. Urology 2005; 65:1131-6.

  100. Epstein JI, Sanderson H, Carter HB, Scharfstein DO. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 2005; 66:356-60.

  101. Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Pathological outcomes are similar for men in an expectant management program undergoing delayed surgical intervention compared to those undergoing immediate intervention. (In press, JNCI 2005).

  102. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ, Metter EJ. Detection of life threatening prostate cancer with PSA velocity: Data from the Baltimore Longitudinal Study of Aging. (Submitted September 2005).

  103. Richman JM, Carter HB, Hanna MN, Murphy JD, Rowlingson AJ, Andrews RAF, Wu CL. Efficacy of Periprostatic Local Anesthetic for Prostate Biopsy Analgesia: a Meta-analysis. (Submitted Oct 2005 to Urology).

  104. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005; 14:2257-60.
TEXTBOOK CHAPTERS
  1. Carter HB and Coffey DS. Prostate Cancer: The magnitude of the problem in the United States. In: A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. Edited by Donald S Coffey, Martin I Resnick, F Andrew Dorr, and James P Karr. New York: Plenum Press, pp. 1-7, 1988.

  2. Carter HB and Coffey DS. Prediction of tumor behavior in prostate cancer. In: Prostate Cancer: The Second Tokyo Symposium. Edited by James P Karr and Hidetoshi Yamanaka. New York: Elsevier, pp. 19-27, 1989.

  3. Coffey DS and Carter HB. New Frontiers In The Treatment of Prostatic Cancer. In: Current Trends and Controversies: The Treatment of Prostatic Cancer. MES Medical Education Services, pp 2-3, 1989.

  4. Coffey DS and Carter HB. Advanced Prostatic Cancer. In: Current Trends and Controversies: The Treatment of Prostatic Cancer. MES Medical Education Services, pp. 32-33, 1989.

  5. Carter HB, Partin AW, Oesterling JE, Weber JP, Epstein JI, Chan DW, Rock RC, and Walsh P.C. The use of prostate specific antigen in the management of patients with prostate cancer: The Johns Hopkins Experience. In: Clinical Aspects Of Prostate Cancer: Assessment Of New Diagnostic And Management Procedures. Edited by William J Catalona, Donald S Coffey, and James P Karr. New York: Elsevier, pp. 247-251, 1989.

  6. Carter HB and Isaacs JT. Prostate cancer: Past, present and future. In: Prostate Cancer: Diagnosis and Therapy. Edited by G Staehler and PG Fabricius. Berlin: Springer-Verlag, pp. 1-8, 1990.

  7. Carter HB and Isaacs JT. Overview of hormonal therapy for prostate cancer. In: Progress In Clinical And Biological Research, Vol. 350. Edited by Hubert G Frohmuller and Manfred P Wirth. New York: Wiley-Liss, Inc., pp. 129-140, 1990.

  8. Pearson JD, Kaminski P, Morrell CH, Carter HB, Metter EJ, Fozard JL, and Brant LJ. Modeling longitudinal rates of change in prostate specific antigen during aging. In: Proceedings of the American Statistical Association Meetings: Social Statistics Section. Alexandria, Va, American Statistical Association; pp. 580-585, 1991.

  9. Carter HB and Walsh PC. Stage A1 prostatic adenocarcinoma. In: Current Therapy In Genitourinary Surgery (2nd edition). Edited by Martin I Resnick and Elroy D Kursh.. Toronto: BC. Decker Inc, pp. 103-105, 1992.

  10. Partin AW, Carter HB, Epstein JI, and Coffey DS. The Biology Of Prostate Cancer: New And Future Directions In Predicting Tumor Behavior. In: Pathology And Pathobiology Of The Urinary Bladder And Prostate. Edited by Ronald S Weinstein and William A Gardner, Jr. Baltimore: Williams and Wilkins, pp. 198-218, 1992.

  11. Carter HB. Evaluation Of The Urologic Patient: Instrumentation And Endoscopy. In: Campbell's Urology (6th edition). Edited by Patrick C Walsh, Alan B Retik, Thomas A Stamey and E Darracott Vaughan. Philadelphia: WB Saunders Co, pp. 331-341, 1992.

  12. Carter HB. Current Status Of PSA In The Management Of Prostate Cancer. In: Advances In Surgery (Vol 27). Edited by John L Cameron. Chicago: Mosby-Year Book Inc, pp. 81-95, 1994.

  13. Carter HB. Ureterolithotomy. In: Operative Urology (2nd edition). Edited by Fray F Marshall. Philadelphia: WB Saunders Co, pp. 352-355, 1996.

  14. Partin AW and Carter HB. Prostate-specific antigen: Use of PSA Density and PSA Velocity. In: Comprrehensive Textbook of Genitourinary Oncology. Edited by Nicholas J Vogelzang, Peter T Scardino, William U Shipley and Donald S Coffey. Baltimore: Williams and Wilkins, pp. 680-684, 1996.

  15. Carter HB and Pearson JD. PSA and the natural course of prostate cancer. In: Recent advances in prostate cancer and BPH. Edited by Fritz H Schroder. New York: Parthenon Publishing Group, pp. 187-193, 1997.

  16. Carter HB and Partin AW. Can progression of prostate cancer be predicted by pre-treatment parameters. In: Recent advances in prostate cancer and BPH. Edited by Fritz H Schroder. New York: Parthenon Publishing Group, pp. 215-224, 1997.

  17. Carter HB. Evaluation Of The Urologic Patient: Instrumentation And Endoscopy. In: Campbell's Urology (7th edition). Edited by Patrick C Walsh, Alan B Retik, Alan J Wein and E Darracott Vaughan, Jr. Philadelphia: WB Saunders Co (In Press).

  18. Carter HB and Partin AW. Diagnosis and Staging of Prostate Cancer. In: Campbell'sUrology (7th edition). Edited by Patrick C Walsh, Alan B Retik, Alan J Wein and E Darracott Vaughan, Jr. Philadelphia: WB Saunders Co (In Press).

  19. Brendler CB and Carter HB. Urological Cancers. In: The Principles and Practice of Medicine, 23rd Edition. Edited by John D Stobo, Thomas A Traill, David B Hellmann, Paul W Ladenson, Brent G Petty. Norwalk: Appleton and Lange, Inc, pp. 790-796, 1996.

  20. Carter HB and Walsh PC. The epidemiology of prostate cancer in Jamaicans. In: Advanced Therapy of Prostatic Disease. Edited by Martin I Resnick and Ian M Thompson: BC Decker, Inc (in press).

  21. Carter HB. Evidence-Based Surgery: Urology. In: Evidence-Based Surgery. Edited by Toby A Gordon and John L Cameron: BC Decker, Inc (in press).

  22. Rodriguez R and Carter HB. The current management of carcinoma of the prostate. In: Advances In Surgery (Vol 28). Edited by John L Cameron. Chicago: Mosby-Year Book Inc, (in press).

  23. Schoenberg MP and Carter HB. Urological Cancers. In: The Principles and Practice of Medicine, 24th Edition. Edited by John D Stobo, Thomas A Traill, David B Hellmann, Paul W Ladenson, Brent G Petty. Norwalk: Appleton and Lange, Inc, (in press).

     

  24. Chan DY and Carter HB. Urologic Complications. In: Advanced Therapy of Inflammatory Bowel Disease, 2nd Edition. Edited by Theodore M Bayless and Stephen B Hanauer. Ontario: BC Decker, Inc, pp. 321-323, 2001.

  25. Denis L, Mettlin C, Carter HB, De Koning HJ, Fourcade R, Fournier G, Hugosson J, Koroltchouk V, Moul R, Stephenson R. Early detection and screening. In: Prostate Cancer: 2nd International Consultation on Prostate Cancer 1999. Edited by G Murphy, S Khoury, A Partin, L Denis. Plymouth, United Kingdom: Plymbridge Ltd, pp. 219-234, 2000.

  26. Carter HB. Basic Instrumentation and Cystoscopy. In: Campbell's Urology (8th edition). Edited by Patrick C Walsh, Alan B Retik, Alan J Wein and E Darracott Vaughan, Jr. Philadelphia: WB Saunders Co, pp.111-119, 2002.

     

  27. Carter HB and Partin AW. Diagnosis and Staging of Prostate Cancer. In: Campbell'sUrology (8th edition). Edited by Patrick C Walsh, Alan B Retik, Alan J Wein and E Darracott Vaughan, Jr. Philadelphia: WB Saunders Co, pp. 3055-3064, 2002.

     

  28. Nelson WG, Carter HB, DeWeese TL, Bajaj G, Thompson TL, Eisenberger MA. Prostate Cancer. In: Clinical Oncology (3rd edition). Edited by Martin D Abeloff, James O Armitage, John E Niederhuber, Michael B Kastan and W Gillies McKenna. Philadelphia: Elsevier Churchill Livingstone, pp.2085-2148, 2004.

     

  29. Carter HB. Postprostatectomy Radiotherapy (commentary). In: Management of Prostate Cancer: Advances and Controversies. Edited by Kenneth B Cummings. New York: Marcel Dekker, pp. 302-304, 2005.
ABSTRACTS AND OTHER PUBLICATIONS
  1. Carter HB and Coffey DS. A new method to predict metastatic potential in aspirated prostatic cancer cells: Cell surface charge. J Urol, 139:191A (abstract #115), 1988.

  2. Carter HB, Hamper UM, Sheth S, Sanders RC, Epstein JI, and Walsh PC. Assessing the accuracy and limitations of ultrasound in screening for prostate cancer. J Urol, 141:276A (abstract #428), 1989.

  3. Brem RF, Tempany CM, Yang A, Carter HB, Epstein JI, Walsh PC, and Zerhouni EA. Magnetic resonance imaging in the detection of occult prostate cancer. J Urol, 143:195A (abstract #26), 1990.

  4. Carter HB, Partin AW, Epstein JI, Chan DW, and Walsh PC. PSA predicts residual tumor volume in stage A prostate cancer. J Urol, 143:206A (abstract #70), 1990.

  5. Larsen MP, Carter HB, and Epstein JI. Stage A1 (incidental) carcinoma of the prostate: Findings at radical prostatectomy. J Urol, 145:214A (abstract #8), 1991.

  6. Carter HB, Andres R, Metter EJ, Fozard JL, Chan DW, and Walsh PC. Early detection of prostate cancer using serial PSA measurements. J Urol, 145:382A (abstract # 679), 1991.

  7. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, and Walsh PC. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. J Urol, 147:417A (abstract #817), 1992.

  8. Carter HB. Prostate Specific Antigen. The Medical Letter, October 2, 1992.

  9. Pearson JD, Brant LJ, Metter EJ, Fozard JL, and Carter HB. Longitudinal patterns of change as a research tool: Prostate specific antigen, prostate disease, and aging. Am J Phys Anth, Supplement 14:130-131, 1992.

  10. Carter HB, Morrell CH, Pearson JD, Plato CC, Metter EJ, Chan DW, Fozard JL, and Walsh PC. Estimation of prostate growth using serial PSA measurements. J Urol, 147:250A (146), 1992.

  11. Cadeddu J, Pearson J, Partin A, Epstein J, and Carter B. Relationship between changes in prostate specific antigen and prognosis of men with prostate cancer. J Urol, 149:301A (abstract #352), 1993.

  12. Steiner MS, Burnett AL, Brooks JD, Brendler CB, Stutzman RE, and Carter HB. Tubularized neourethra following radical retropubic prostatectomy. J Urol, 149:378A (abstract #663), 1993.

  13. Ronnett BM, CarMichael M, Carter HB, and Epstein JI. Does prostatic intraepithelial neoplasia (PIN) result in elevated serum prostate specific antigen (PSA) levels? J Urol, 149:414A (abstract #804), 1993.

  14. Mandell K, Partin A, Hill G, Epstein J, Stutzman R, Carter HB, and Walsh PC. PSA density in BPH: Correlation with stromal epithelial ratios and influence of age. J Urol, 149:448A (abstract #943), 1993.

  15. Marshall FF, Partin AW, Steiner M, Hsieh K, Simons JW, Lumadue J, and Carter HB. Serum ferritin as a clinical marker for renal cell carcinoma: Influence of tumor volume. J Urol, 151:259A (abstract # 127), 1994.

  16. Carter HB, Stutzman RE, and Mostwin JL. Functional and radiographic properties of a tubularized neourethra after radical prostatectomy. J Urol, 151:270A (abstract #170), 1994.

  17. Carter HB, Pearson JD, X Waclawiw, Metter EJ, Guess HA, and Walsh PC. PSA variability in men with BPH. J Urol, 151:312A (abstract #340), 1994.

  18. Cadeddu J, Pearson J, Lee B, Landis P, Partin A, Epstein J, and Carter B. Relationship between PSA velocity and the percent of prostatic epithelium in men with BPH. J Urol, 151:313A (abstract #341), 1994.

  19. Pearson JD, Brant LJ, Landis PK, and Carter HB. Comparison of PSA screening criteria in men with BPH and prostate cancer. J Urol, 151:448A (abstract #883), 1994.

  20. Carter HB. Techniques for preservation of urinary continence after radical retropubic prostatectomy: Tubularized neourethra. Atlas of the Urologic Clinics of North America, 2:53-58, 1994.

  21. Carter HB. Diagnosis of prostate cancer (editorial). J Urol, 152:1168-1169, 1994.

  22. Partin AW and Carter HB. Prostate-specific antigen: Use in clinical practice. In: Campbell's Urology Updates (6th edition). Edited by Patrick C Walsh, Alan B Retik, Thomas A Stamey and E Darracott Vaughan Jr. Philadelphia: WB Saunders Co, pp. 1-12, 1994.

  23. Hortopan S, Partin AW, Carter HB, and Marshall FF. Minilap incision for radical retropubic prostatectomy (RRP): Report of first 107 cases with respect to extent of lymphadenectomy and surgical margin status. J Urol, 153:384A (abstract #622), 1995.

  24. Carter HB, Pearson JD, Morrell CH, Brant LJ, Gruer PJK, Guess HA. What is the shortest time interval over which PSA velocity should be measured? J Urol, 153:419A (abstract #764), 1995.

  25. Pearson JD, Carter HB, Metter EJ, Chan DW, Landis P, Andres R, and Walsh PC. Sensitivity and specificity of age-specific reference ranges for PSA velocity. J Urol, 153:465A (abstract #947), 1995.

  26. Pearson JD, Blackman M, Metter EJ, Waclawiw Z, Carter HB, and Harman SM. Effects of age and cigarette smoking on longitudinal changes in androgens and SHBG in healthy men.. The Endocrine Society 77th Annual Meeting Program and Abstracts, page 323, 1995.

  27. Pearson JD, Waclawiw Z, Landis P, Chan DW, and Carter HB. Factors affecting day-to-day variability in serum prostate-specific antigen levels. Am J Hum Biol, 7:132, 1995.

  28. Russell S, Waclawiw Z, Carter HB, and Pearson JD. Age differences in average and maximum urinary flow rates in men with and without benign prostatic hyperplasia. Am J Hum Biol, 7:133, 1995.

  29. Partin AW, Subong ENP, Jones KA, Marschke PLS, Epstein JI, Chan DW, Carter HB, and Luderer AA. Free/Total PSA does not improve the prediction of final pathological stage for men with localized prostate cancer. J Urol, 155:415A (abstract #419), 1996.

  30. Partin AW, Subong ENP, Kelley CA, Hortopan S, Carter HB, Chan DW, Walsh PC, Rittenhouse HG, Wolfert RL, Gasior GH, and Southwick P. Prospective analysis of free PSA to total PSA ratio for prostate cancer detection and the clearance rate of free PSA after radical prostatectomy. J Urol, 155:416A (abstract #422), 1996.

  31. Carter HB, Epstein J, Sauvageot J, and Walsh P. Evaluation of men with stage T1c prostate cancer. J Urol, 155:419A (abstract #434), 1996.

  32. Thiel R, Pearson J, Carter B, Epstein J, and Walsh P. Is PSA velocity a marker of prostate cancer stage? J Urol, 155:488A (abstract #708), 1996.

  33. Schoenberg M, Carter HB, Mostwin JL, Burnett AL, and Marshall FF. Male orthotopic ileocolic neobladder post cystectomy: Long term follow-up. J Urol, 155:518A (abstract #828), 1996.

  34. Pearson JD, Partin AW, Chan DW, Luderer AA, and Carter HB. Serial measurements of serum total PSA, free PSA, and free/total PSA ratio in men with and without prostate disease. J Urol, 155:606A (abstract #1179), 1996.

  35. Pearson JD, Brant LJ, Metter EJ, Fozard JL, and Carter HB. Age differences in short-term reliability of urinary flow measurements in men from the Baltimore Longitudinal Study of Aging. Gerontologist, 36(SI 1):3-4, 1996.

  36. Carter HB. Hereditary prostate cancer (editorial). J Urol, 155:1843, 1996.

  37. Carter HB. Cryosurgery for prostate cancer (editorial). J Urol, 156:120, 1996.

  38. Carter HB, Partin AW, Chan DW, Luderer AA, and Pearson JD. Percentage of free PSA in sera predicts cancer aggressiveness: A longitudinal analysis. J Urol, 157(4): (abstract #444), 1997.

  39. Simon I, Christens-Barry WA, Subong ENP, Carter HB, Bluemke DA, Fozard JL, Landis PK, and Partin AW. Non-invasive MRI of the prostate correlates with prostatic histology. J Urol, 157(4): (abstract #739), 1997.

  40. Epstein JI, Walsh PC, Sauvageot J, and Carter HB. Utility of repeat sextant and transition zone biopsy for assessing extent of prostate cancer. J Urol, 157(4): (abstract #1146), 1997.

  41. Pearson JD, Thiel R, Epstein JI, Carter HB, and Walsh PC. Relationship between PSA velocity and tumor significance in men with stage T1C prostate cancer. J Urol, 157(4): (abstract #1165), 1997.

  42. Pearson JD, Fozard JL, Metter EJ, and Carter HB. Appropriate interval for PSA testing among men without evidence of prostatic cancer. J Urol, 157(4):1432, 1997.

  43. Pearson JD, Landis PK, Metter EJ, Fozard JL, Cadeddu J, Partin AW, Epstein JI, and Carter HB. Free/total prostate-specific antigen ratio and prostate composition in men with benign prostatic hyperplasia. Am J Hum Biol, 9(1):141, 1997.

  44. Carter HB. Treatment of Prostate Cancer: A Controversial Issue. J Urol, 158:1476, 1997.

  45. Carter HB. PSA velocity: When should it be utilized. AUA News, 1997.

  46. Carter HB, Epstein JI, Walsh PC, and Partin AW. Age, PSA and chance of curable prostate cancer among men with non-palpable disease. J Urol, 159:74(#279), 1998.

  47. Pearson JD, Landis P, Fozard JL, and Carter HB. When is PSA testing no longer necessary? J Urol, 159:178(#681), 1998.

  48. Hedican SP, Nelson JB, Marshke P, Carter HB, Walsh PC, Partin AW, Luo G, Veltri RW, and O'Hara SM. Evaluation of preoperative prostate cancer staging and postoperative detection of recurrence utilizing the reverse transcriptase polymerase chain reaction (RT-PCR). J Urol, 159:289(#1115), 1998.

  49. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, and Carter HB. Nonpalpable (stage T1c) prostate cancer: Prediction of "insignificant" disease using free/total (F/T) serum PSA levels and biopsy findings. J Urol, 159:293(#1130), 1998.

  50. Carter HB. Accuracy of prostate needle biopsy in predicting extracapsular tumor extension at radical prostatectomy: Application in selecting patients for nerve sparing surgery (editorial). Urology 52:818,1998.

  51. Carter HB. Serial prostate specific antigen screening for prostate cancer: A computer model evaluates competing strategies (editorial). J Urol 162:748, 1999.

  52. Lujan M, Paez A, Sanchez E, Herrero A, Martin E, Berenguer A. Prostate specific antigen variation in patients without clinically evident prostate cancer (editorial). J Urol 162:1313, 1999.

  53. Brooks JD, Metter EJ, Chan DW, Sokoll LJ, Landis P, Nelson WG, Muller D, Andres R, Carter HB. Prediagnostic serum selenium levels and the risk of prostate cancer development. J Urol, 161:69 (#261), 1999.

  54. Ross, KS, Pearson JD, Guess HA, Epstein JI, Carter HB. Rational PSA screening for prostate cancer: computer simulations of age ranges, PSA cutoffs, and testing intervals. J Urol, 161:210 (#803), 1999.

  55. Williams AM, Simon I, Landis PK, Moser C., Christens-Barry, WA, Carter, HB, Metter JE, Partin AW. Prostatic growth rate determined from MRI data: age related longitudinal changes. J Urol, 161:288 (#1116), 1999.

  56. Carter HB, Walsh PC, Epstein JI. Significance of prior negative needle biopsies in men subsequently diagnosed with prostate cancer. J Urol, 161:292 (#1132), 1999.

  57. Lecksell K, Carter HB, Epstein JI. Importance of posterolateral needle biopsies of the prostate in the detection of prostate cancer. J Urol, 161:323 (#1246), 1999.

  58. Ross KS, Guess HA, Pearson JD, Carter HB. Earlier but less frequent PSA testing- Computer simulations of more efficient screening strategies. J Urol 163:88 (#388), 2000.

  59. Feneley MR, Landis PK, Simon I, Metter EJ, Morrell C, Carter HB, Walsh PC. The diagnosis of cancer in the PSA era: Is it driven by tumor volume or BPH? Serendipity? J Urol 163:91 (#397), 2000.

  60. Fang J, Metter EJ, Carter HB. Low levels of prostate specific antigen predict the long term risk of prostate cancer. J Urol 163:238 (#1059), 2000.

  61. Carter HB, Landis PK, Epstein JI, Walsh PC. Expectant management of prostate cancer with curative intent. J Urol 163:335 (#1486), 2000.

  62. Isaacs SD, Wiley KE, Carter HB, Partin AW, Walsh PC, Isaacs WB, Xu J, Gronberg H. Prostate specific antigen values in unaffected men with a strong family history of prostate cancer. J Urol 165:62 (#254), 2001.

  63. Pearson JD, Watson DJ, Corrada MM, Stewart WF, Landis PK, Metter EJ, Carter HB, Platz EA. A prospective cohort study of nonsteroidal anti-inflammatory drugs and risk of prostate cancer: Baltimore Longitudinal Study of Aging. J Urol 165:63 (#259), 2001.

  64. Wright EJ, Fang J, Metter EJ, Partin AW, Landis PK, Chan DW, Carter HB. Prostate specific antigen (PSA) predicts the long term risk of prostate enlargement: Results from the Baltimore Longitudinal Study of Aging. J Urol 165:264 (#1085), 2001.

  65. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria (editorial comment HB Carter). Urology 2001; 58:424.

  66. Carter HB, Metter EJ, Wright J, Landis P, Walsh PC. PSA and All Cause Mortality: Results from the Baltimore Longitudinal Study of Aging. J Urol 169:367(#1373), 2003.

     

  67. Parsons JK, Carter HB, Landis P, Wright EJ, Platz EA, Metter EJ. Higher serum free testosterone is associated with an increased risk of prostate cancer: Results from the Baltimore Longitudinal Study On Aging. J Urol 171:116(#439), 2004.

     

  68. Ross KS, Guess HA, Carter HB. Estimation of treatment benefits when prostate cancer screening is discontinued at different ages. J Urol 171:171(#644), 2004.

     

  69. Allaf ME, Carter HB, Walsh PC. Anatomic extent of lymph node dissection: Impact on men with clinically localized prostate cancer. J Urol 171:221(#838), 2004.

     

  70. Carter HB, DeMarzo AM, Lilja H. Detection, Diagnosis, and Prognosis of Prostate Cancer. In: Report to the Nation on Prostate Cancer 2004. Edited by Peter R Carroll and William G Nelson. Medscape, pp 9-20, 2004.

     

  71. Freedland SJ, Haffner MC, Landis PK, Saigal CS, Carter HB. Obesity does not negatively impact on health related quality of life outcomes after anatomic retropubic radical prostatectomy. J Urol 173:53(#194), 2005.

     

  72. Freedland SJ, Haffner MC, Landis PK, Saigal CS, Carter HB. Health related quality of life outcomes after anatomic retropubic radical prostatectomy: Impact of neurovascular bundle preservation. J Urol 173:199(#730), 2005.

     

  73. Carter HB, Ferrucci L, Metter EJ. PSA velocity and risk of prostate cancer death in the Baltimore Longitudinal Study of Aging. J Urol 173:257(#951), 2005.

     

  74. Parsons JK, Carter HB, Partin AW, Metter EJ, Landis PK, Platz EA. Obesity is a predictor of increased prostate volume. J Urol 173:346(#1278), 2005.

  75. Carter HB. PSA scores: should we use a lower threshold? Johns Hopkins Med Lett Health After 50 2004; 17(8):6.

  76. Carter HB. Editorial comment. Konety BR, Bird VY, Deorah S, Dahmoush L. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J Urol 2005; 174:1785-1788.


INVITED LECTURES AND SPECIAL PRESENTATIONS

  1. The Use of PSA in the Management of Prostate Cancer. National Cancer Institute Conference on Prostate Cancer, Prouts Neck, Maine, October, 1988.

  2. Ureteropyeloscopy: Role in Diagnosis and Therapy of Urologic Disease. Surgical Grand Rounds, Johns Hopkins Hospital, December 9, 1989.

  3. Nonoperative Treatment of BPH. Medical Grand Rounds, Washington Adventist Hospital, April 20, 1990.

  4. The Natural History of Stage A1 Prostate Cancer: The Johns Hopkins Experience. Urologic Oncologic Workshop, Berlin, West Germany, June 9, 1990.

  5. Management of Stage A Prostate Cancer. Current Concepts in Prostate Cancer. Annual Urologic Conference, Thomas Jefferson University, Philadelphia, October 25, 1990.

  6. Surgical Management of Urolithiasis. Topics in Nephrology Conference, Francis Scott Key Hospital, January 29, 1991.

  7. Medical and Surgical Management of Nephrolithiasis. Medical Grand Rounds, Department of Medicine, Johns Hopkins University School of Medicine, March 8, 1991.

  8. Prostatism: Evaluation and Management. Topics In Ambulatory Medicine, Johns Hopkins Hospital, Baltimore, MD, April 10-12, 1991.

  9. Management of Renal Calculi. Topics in Clinical Medicine, Department of Medicine, Johns Hopkins University School of Medicine, May 7, 1991.

  10. Longitudinal Evaluation Of PSA In Men With And Without Prostate Disease. Department Of Urology Grand Rounds, Baylor College Of Medicine, Houston, Texas, July 26, 1991.

  11. New Approaches To The Early Diagnosis of Prostate Cancer: The Value of PSA. Department of Surgery Grand Rounds, Johns Hopkins Hospital, September, 14, 1991.

  12. New Approaches To The Early Diagnosis of Prostate Cancer: The Value of PSA. Department of Medicine Grand Rounds, Johns Hopkins Hospital, September 20, 1991.

  13. Urologic Approach To Renal Stone Disease. Department of Cardiovascular and Interventional Radiology Grand Rounds, Johns Hopkins Hospital, October 23, 1991.

  14. PSA In The Early Diagnosis Of Prostate Cancer. Maryland Urological Meeting, Johns Hopkins Hospital, November 16, 1991.

  15. The Use of PSA in Management of Prostate Cancer. Department of Medicine Grand Rounds, Johns Hopkins Hospital, February 1, 1992.

  16. PSA In The Early Diagnosis of Prostate Cancer. Diagnosis and Treatment of Neoplastic Disorders (18th Annual Symposium); The Johns Hopkins Oncology Centers, April 2-3, 1992.

  17. Rate Of Change In Prostate Specific Antigen: A Novel Approach For The Earlier Detection Of Prostate Cancer. PSA Symposium, American Urological Association annual meeting, Washington, D.C., May 9, 1992.

  18. Screening For Prostate Cancer. Topics In Clinical Medicine, Department of Medicine, Johns Hopkins Hospital, May 15, 1992.

  19. Advances In Diagnosis And Treatment Of Prostate Cancer. Providence Hospital CME Conference, Washington, D.C., May 28, 1992.

  20. Longitudinal Evaluation of Prostate Specific Antigen Levels In Men With and Without Prostate Disease. Symposium on Benign Prostatic Hyperplasia. Robert Wood Johnson University Hospital, June 12 and 13, 1992.

  21. Prostate Examination: 1992. Topics In Gastroenterology And Liver Disease. Johns Hopkins Hospital, September 30-October 2, 1992.

  22. Longitudinal Studies Of PSA. Molecular Biology And Natural History Of Prostate Cancer Seminar of the National Cancer Institute, Prout's Neck, Maine, October 15-18, 1992.

  23. Screening For Prostate Cancer: Use Of PSA. Texas Club Of Internists, Harbor Court Hotel, Baltimore, Maryland, October 22, 1992.

  24. Screening For Prostate Cancer. Cancer Update For The Primary Care Physician, Centre Community Hospital, State College, PA., October 28, 1992.

  25. Surgery As Treatment Of Early Prostate Cancer. Cancer Update For The Primary Care Physician, Centre Community Hospital, State College, PA., October 28, 1992.

  26. Current Status Of PSA In The Diagnosis And Management Of Prostate Cancer. Roper Cancer Symposium, Charleston, S.C., October 31, 1992.

  27. Longitudinal Evaluation Of Changes In PSA. Roper Cancer Symposium, Charleston, S.C., October 31, 1992.

  28. Prevention of Urinary Tract Calculi. Department of Cardiovascular and Interventional Radiology Grand Rounds, Johns Hopkins Hospital, January 28, 1993.

  29. Identifying Markers For Prostatic Diseases. Consultants Meeting For Benign Prostatic Hyperplasia And Other Chronic Disorders Of Aging, Amelia Island, Florida, February 26, 1993.

  30. Prostate Specific Antigen And Prostate Cancer. Annual Meeting Of American Urological Association, San Antonia, Texas, May 15, 1993.

  31. Prostate Cancer: Early Detection, Evaluation and Surgical Management. Prostate Cancer 1993 (Washington Adventist Hospital Conference), Bethesda, Maryland, November 5, 1993.

  32. Prostate Cancer: Early Detection, Evaluation and Management. 21st Annual Geriatrics Symposium: A Board Review, Baltimore, Maryland, Jan 24-28, 1994

  33. Update On The Use Of PSA. Surgical Grand Rounds, Johns Hopkins Hospital, February 19, 1994.

  34. The Use Of PSA In Men With Prostate Cancer. Prostate Cancer Symposium, Lenox Hill Hospital, New York, N.Y., September 29, 1994.

  35. Do We Detect Insignificant Prostate Cancer With PSA? International Symposium On Prostate Cancer, Munich, Germany, October 14-15, 1994.

  36. Anatomic Approach To Radical Prostatectomy, International Symposium On Prostate Cancer, Munich, Germany, October 14-15, 1994.

  37. Prostate Cancer: Surgical View. Advances and Controversies in Primary Care Geriatrics, Baltimore Maryland, February 3, 1994.

  38. Screening For Prostate Cancer. Medical Grand Rounds at The Naval Hospital, Bethesda, Maryland, February 16, 1995.

  39. PSA Velocity. Prostate Cancer Controversies, Baylor University Medical Center, Dallas, Texas, March 22, 1996.

  40. PSA in Staging Prostate Cancer. Prostate Cancer Controversies, Baylor University Medical Center, Dallas, Texas, March 22, 1996.

  41. PSA and The Natural Course of Prostate Cancer. Progress and Controversies in Oncological Urology, Rotterdam, Netherlands, April 11-13, 1996.

  42. Can Progression of Prostate Cancer be Predicted by Pre-Treatment Parameters. Progress and Controversies in Oncological Urology, Rotterdam, Netherlands, April 11-13, 1996.

  43. Evaluation of Men With Stage T1c Prostate Cancer. Grand Rounds Urology, Johns Hopkins Hospital, October 29, 1996.

  44. Early Detection of Prostate Cancer With PSA Screens. Men's Health Symposium, Baltimore, Maryland, November 11, 1996.

  45. Cancer in the New Millenium. JAMA press conference. New York, N.Y., May 13, 1997.

  46. Non-Palpable Prostate Cancer in the PSA Era. Surgical Ground Rounds at Johns Hopkins Hospital, November 8, 1997, Baltimore, MD.

  47. Watchful Waiting For Men With Non-Palpable Prostate Cancer. Maryland Urological Association, November 22, 1997, Baltimore, MD.

  48. Diagnosis and Management of Prostate Cancer in the PSA Era. Grand Rounds, Naval Hospital, March 12, 1998, Bethesda, MD.

  49. PSA Testing. Grand Rounds, Johns Hopkins Hospital, August 11, 1998, Baltimore, MD.

  50. New Aspects of Prostate Cancer Management, State of the Art Lecture, James C. Kimbrough Urologic Seminar, October 15, 1998, Williamsburg, Virginia.

  51. Prostate Cancer Controversies in the PSA Era. The Bernard Kleiman Symposium on Men's Health Care. Saturday, February 20, 1999, Baltimore, Maryland.

  52. Prostate Cancer Early Detection: National Comprehensive Cancer Network Guidelines (4th Annual Conference). Saturday, February 26, 1999, Fort Lauderdale, Florida.

  53. Guidelines for Early Detection of Prostate Cancer. Grand Rounds at the Bethesda Naval Hospital, Department of Urology. Thursday, March 11, 1999, Bethesda, MD.

  54. Interpretation and Misinterpretation of a PSA assay. 3rd Annual Men's Health 1999. Johns Hopkins University, April 9, 1999, Baltimore, MD.

  55. Early Detection of Prostate Cancer. Current Treatment of Prostate Cancer. Mid-Hudson Health Cancer Center, Poughkeepsie, New York, October 20, 1999.

  56. Early Detection of Prostate Cancer and Expectant Management for Localized Disease. Medicine Grand Rounds at the Johns Hopkins Hospital. October 23, 1999.

  57. Comparative efficiency of prostate specific antigen screening strategies for prostate cancer detection. Maryland Urological Meeting, Johns Hopkins Hospital, November 13, 1999.

  58. Prostate Cancer: State of the Art. Renophobia Relief, Johns Hopkins Hospital, November 15, 1999.

  59. PSA Effect on Prostate Cancer Statistics and Evolution of PSA Screening. Urology Grand Rounds, Johns Hopkins Hospital, February 29, 2000.

  60. Management of rising PSA after definitive therapy for prostate cancer. US TOO Public Symposium, Washington DC, June 10, 2000.

  61. Expectant Management of Prostate Cancer. Heinrich Warner Symposium, Hamburg, Germany, November 3, 2000.

  62. Visiting Professor. Epindorff University, Hamburg, Germany, November 2.

  63. Prevention, Diagnosis, and Management of Prostate Cancer. Kronos Foundation. Phoenix, Arizona, February 23, 2001.

  64. Early Diagnosis of Prostate Cancer. Topics in Clinical Medicine, Johns Hopkins School of Medicine, Baltimore MD, May 10, 2001.

  65. Early Diagnosis of Prostate Cancer. Medicine Grand Rounds. Johns Hopkins School of Medicine, Baltimore MD, Novermber10, 2001.

  66. Rationale for Earlier and Less Frequent PSA Testing. Maryland Urological. Johns Hopkins School of Medicine, Baltimore MD, Novermber10, 2001.

  67. Early Detection of Prostate Cancer. New Perspectives on Prostate Cancer Symposium. Washington Adventist Hospital, November 16, 2001.

  68. Surgical Management of Prostate Cancer. New Perspectives on Prostate Cancer Symposium. Washington Adventist Hospital, November 16, 2001.

  69. Primary and Secondary Prostate Cancer Prevention. Visiting Professor at Center for Prostate Disease Research, Bethesda MD, December 15, 2001.

  70. Prostate Cancer Screening: Rationale and Strategy. Surgical Grand Rounds, Johns Hopkins School of Medicine, September 7, 2002.

  71. Diagnosis and Management of Prostate Cancer in the PSA era. The World Bank, Washington DC, November 20, 2002.

  72. PSA For Early Detection of Prostate Cancer. Multidisciplinary Advances in the Treatment of Prostate Cancer. University of N.C., January 31-February 1, 2003.

  73. Surgery for Clinically Localized Prostate Cancer. Multidisciplinary Advances in the Treatment of Prostate Cancer. University of N.C., January 31-February 1, 2003.

  74. Diagnosis and Management of Prostate Cancer in the PSA Era. Urology Nursing Society, Baltimore MD, April 10-11, 2003.

  75. Problem Cases in Prostate Cancer: Panel Discussion at Annual American Urological Association Meeting. Chicago, Ill, April 30, 2003.

  76. 48th Annual Philip A Tumulty Topics In Clinical Medicine. Diagnosis and Management of Prostate Cancer in the PSA Era. Turner Auditorium, Johns Hopkins School of Medicine, May 8, 2003.

  77. Reconstructive Surgery of the Urogenital Tract: International Symposium With Live Surgery. Performance of radical prostatectomy (Live-Surgery) May 23; Prostate Cancer Screening: Fact and Fiction (Talk) May 24. Department of Urology, University Hospital Grosshadern, Ludwig-Maximillians-University; Munich, Germany, May 23-24.

  78. Detection and Treatment of Prostate Cancer. South Carolina Urological Association Annual Meeting, Columbia, SC, September 17, 2003.

  79. Prostate Cancer Screening: Personal Views. Invited lecture at Free University Medical Center, Amsterdam Netherlands, October 30, 2003.

  80. Expectant Management of Prostate Cancer With Curative Intent. Maryland Urological Association Meeting. Baltimore MD, November 22, 2003.

  81. Expectant Management of Prostate Cancer With Curative Intent. Engadin Prostate Cancer Symposium. Zuoz, Switzerland, March 3-7, 2004.

  82. Expectant Management of Prostate Cancer With Curative Intent: The Johns Hopkins Experience. Urology Grand Rounds, Johns Hopkins Hospital, April 8, 2004.

  83. An Update on Prostate Cancer. Topics In Clinical Medicine. Johns Hopkins Hospital, May 6, 2004.

  84. Expectant Management of Prostate Cancer With Curative Intent: The Johns Hopkins Experience. Urological Club of Great Britain and Ireland, Annual Meeting. Dublin, Ireland (Guest Speaker), September 16-17, 2004.

  85. Biochemical Recurrence of Prostate Cancer. Mid Atlantic Section of American Urological Association (speaker). Cambridge, MD, October 3-6, 2004.

  86. Update on Prostate Cancer. Topics in Clinical Medicine, Johns Hopkins School of Medicine. May 5, 2005.

  87. Watchful Waiting for Prostate Cancer: Course #861C American Urological Association annual meeting. San Antonio, TX, May 25, 2005.

  88. Surgery or Watchful Waiting for Prostate Cancer. National Conference on Prostate Cancer. Omni Shoreham Hotel, Washington DC, June 17, 2005.

  89. Prostate Cancer Update. Clinical Issues in Primary Care (Pri-Med). Baltimore Convention Center, Baltimore MD, October 6-8, 2005.

  90. Early Detection of Prostate Cancer: How and when do we screen? New Perspectives on Prostate Cancer, Washington Adventist Hospital, Bethesda MD, November 3, 2005.

  91. Prostate Cancer Surgery: Indications and Technique. New Perspectives on Prostate Cancer, Washington Adventist Hospital, Bethesda MD, November 3, 2005.

  92. Expectant Management of Prostate Cancer. Advances in Urology 2005. Emory University School of Medicine. Atlanta, Georgia, December 2-3, 2005.

  93. PSA Kinetics. Advances in Urology 2005. Emory University School of Medicine. Atlanta, Georgia, December 2-3, 2005.

 
© Copyright 2009 | All Rights Reserved | Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287